




Using IMP-3 as a therapeutic target for patients with melanoma

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI: Prof. Chia-Yu Chu
Department of Dermatology, National Taiwan U.

Experience:



http://epaper.ntuh.gov.tw/health/201012/special_2_1.html

Market Needs:

Amongst skin cancers, cutaneous melanoma is the most frequent cause of mortality. The most common histological subtype of melanoma among Asian populations is acral lentiginous melanoma, which have a grave prognosis.

Our Technology:

IMP-3 expression is a strong prognostic factor for melanoma, especially the acral lentiginous melanoma.

Strength:

Targeting IMP-3 might offer a potentially feasible and effective approach to the clinical management of melanoma.

Competing Products:

Non

Intellectual Properties:

- (1) We conducted several studies to explore melanoma pathogenesis
- (2) Provisional patent application (US 62/275,772)

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.